Gastrointestinal Drugs Market Rate, Manufacturers, Sales and Forecasts by 2025

Market Analysis 

The global gastrointestinal drugs market is predicted to touch USD 59,300 million at a 4.9% CAGR between 2019- 2025, reveals the new Market Research Future (MRFR) report. Gastrointestinal (GI) diseases affect the pancreas, gallbladder, liver, esophagus, rectum, large intestine, and stomach. Some of its symptoms include constipation, bloating, indigestion, heartburn, and others. Gastrointestinal drugs, simply put, are medicines utilized to treat irritable bowel syndrome, constipation, hemorrhoids, perianal infections and fissures, diverticular disease, and ulcerative colitis. 

Various factors are adding to the global gastrointestinal drugs market share. These factors, as per the new MRFR report, include rising prevalence of gastrointestinal diseases worldwide, increasing investments in research for the development & expansion of gastrointestinal drugs, growing knowledge regarding the accessibility of the treatments and healing process, and technological advances in the treatment process. Additional factors adding market growth include rising awareness about gastrointestinal disease & availability of treatments, emerging generic drugs owing to its cost-effectiveness, increasing cases of irritable bowel syndrome, development in biologics, increasing cases of rectal related diseases, and the increasing number of tumors & surgeries. 

Market Segmentation 

The MRFR report provides an inclusive segmental analysis of the global gastrointestinal drugs market based on end user, disease type, route of administration, and drug category. 

By drug category, the gastrointestinal drugs market is segmented into anti-inflammatory drugs, antiemetic, laxatives and antidiarrheal, acid neutralizers, and others. Acid neutralizers are again segmented into proton pump inhibitors, H2 antagonists, antacids, and others. Of these, antacids will lead the market over the forecast period for its increasing demand owing to its easy availability and people’s unhealthy imbalance eating habits. 

By route of administration, the gastrointestinal drugs market is segmented into rectal, parenteral, and oral. 

By disease type, the gastrointestinal drugs market is segmented into inflammatory bowel disease, gastroesophageal reflux disease, and others. Of these, the gastroesophageal reflux disease will dominate the market over the forecast period. 

By end user, the gastrointestinal drugs market is segmented into retail pharmacies, hospital pharmacies, and others. 

Key Players

Key players profiled in the global gastrointestinal drugs market report include Boehringer Ingelheim GmbH (Germany), GlaxoSmithKline Plc. (UK), Janssen Biotech (US), Sanofi (France), Valeant Pharmaceuticals (US), Eisai Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), Janssen Biotech Inc. (US), Bayer AG (Germany), Allergan Plc (US), Abbott Laboratories(US), Valeant (US), Johnson & Johnson (US), AstraZeneca (UK), and AbbVie Inc. (US). 

Article source: https://article-realm.com/article/Sports-Recreation/13108-Gastrointestinal-Drugs-Market-Rate-Manufacturers-Sales-and-Forecasts-by-2025.html